EBA
PTGX icon

Eagle Bay Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Eagle Bay Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$7.91K – 957
2022
Q2 		$7.91K Hold
1,000
– – ﹤0.01% 678
2022
Q1 		$24K Hold
1,000
– – 0.02% 223
2021
Q4 		$34K Buy
1,000
+760
+317% +$24K 0.02% 466
2021
Q3 		$4K Buy
+240
New +$10.2K ﹤0.01% 876

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eagle Bay Advisors's PTGX Position: Q3 2022 in Review

Eagle Bay Advisors sold out of Protagonist Therapeutics (PTGX) in Q3 2022, closing a stake of 1,000 shares — an estimated $7.91K sold.

Eagle Bay Advisors first reported a position in PTGX in Q3 2021 and held it in 4 quarters. The position peaked at $34K in Q4 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q3 2022.

  • Eagle Bay Advisors reported no remaining Protagonist Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Eagle Bay Advisors sold 1,000 Protagonist Therapeutics shares in Q3 2022, an estimated $7.91K.
  • Eagle Bay Advisors first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 4 quarters.
  • Eagle Bay Advisors's Protagonist Therapeutics position peaked at $34K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2022.

Based on Eagle Bay Advisors's 13F filing for Q3 2022, filed 23 Nov 2022.